Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Sickle Cell Disease Pipeline Drugs Market Overview
Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain, and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion, and stem cell transplant.
The Sickle Cell Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects.
Sickle Cell Disease Pipeline Drugs Market Segmentation by Targets
Some of the targets in the Sickle Cell Disease pipeline are Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin among others. Hemoglobin Subunit Beta was the largest target in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Targets
For more Sickle Cell Disease pipeline drugs market target insights, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the mechanisms of action in the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator among others. Hemoglobin Subunit Beta Activator was the leading MoA in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Mechanisms of Action
For more MoA insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Sickle Cell Disease pipeline drugs market are intravenous, oral, subcutaneous, topical, and parenteral among others. The majority of the pipeline drugs followed the oral route of administration.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Sickle Cell Disease pipeline drugs market are small molecule, gene-modified cell therapy, gene therapy, cell therapy, and monoclonal antibody among others. Small molecule was the leading molecule type in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Sickle Cell pipeline drugs market are Beam Therapeutics Inc, Agios Pharmaceuticals Inc, CRISPR Therapeutics AG, Editas Medicine Inc, Global Blood Therapeutics Inc, and Novartis AG. Among these, Global Blood Therapeutics Inc had the most number of products under development in 2022.
Sickle Cell Disease Pipeline Drugs Market Analysis by Key Companies
To know more about the Sickle Cell Disease pipeline drugs market companies, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Report Overview
| Key Targets | Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin |
| Key Mechanism of Actions | Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator |
| Key Routes of Administration | Intravenous, Oral, Subcutaneous, Topical, and Parenteral |
| Key Molecule Types | Small Molecule, Gene-Modified Cell Therapy, Gene Therapy, Cell Therapy, and Monoclonal Antibody |
| Key Companies | Beam Therapeutics Inc, Agios Pharmaceuticals Inc, CRISPR Therapeutics AG, Editas Medicine Inc, Global Blood Therapeutics Inc, and Novartis AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Agios Pharmaceuticals Inc
Alfasigma SpA
Alkermes Plc
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
AntiRadical Therapeutics LLC
Ascentage Pharma Group Inc
Asklepion Pharmaceuticals LLC
Aviceda Therapeutics Inc
Axcella Health Inc
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
bluebird bio Inc
Brooklyn ImmunoTherapeutics Inc
C4X Discovery Holdings Plc
Cannabis Science Inc
Cell Source Inc
Cellectis SA
Cetya Therapeutics Inc
Chugai Pharmaceutical Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Cyclerion Therapeutics Inc
Daiichi Sankyo Co Ltd
Editas Medicine Inc
Emmaus Life Sciences Inc
Epidestiny Inc
Epizyme Inc
Forma Therapeutics Inc
Fulcrum Therapeutics Inc
Functional Fluidics LLC
Gamida Cell Ltd
Garuda Therapeutics Inc
Gilead Sciences Inc
Global Blood Therapeutics Inc
Glycan Therapeutics Inc
GlycoMimetics Inc
Graphite Bio Inc
GreenLight Biosciences Holdings PBC
Guangzhou Dazhou Biomedical Technology Co Ltd
Hartis Pharma SA
Hillhurst Biopharmaceuticals Inc
Homology Medicines Inc
IHP Therapeutics Inc
IllExcor Therapeutics LLC
Imago BioSciences Inc
Intellia Therapeutics Inc
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
KM Biologics Co Ltd
Medeor Therapeutics Inc
Merck & Co Inc
Micelle BioPharma Inc
MimeTech Srl
Mind Biosciences LLC
Mitobridge Inc
Modus Therapeutics AB
Molecules For Health Inc
Monte Rosa Therapeutics Inc
NicOx SA
Novartis AG
NuvOx Pharma LLC
Oryzon Genomics SA
Pfizer Inc
PHD Biosciences
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Rare Partners Srl
Regenacy Pharmaceuticals LLC
ReNeuroGen LLC
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Sangamo Therapeutics Inc
Secura Bio Inc
Shanghai Bendao Gene Technology Co Ltd
Syros Pharmaceuticals Inc
Tarus Therapeutics Inc
ThioLab LLC
TransThera Sciences (Nanjing) Inc
Vanguard Therapeutics Inc
Vera Therapeutics Inc
Vertex Pharmaceuticals Inc
Vifor Pharma Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Sickle Cell Disease pipeline drugs market?
Some of the key targets of the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin.
-
What are the key mechanisms of action in the Sickle Cell Disease pipeline drugs market?
Some of the key mechanisms of action in the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator.
-
What are the key routes of administration in the Sickle Cell Disease pipeline drugs market?
The key routes of administration in the Sickle Cell Disease pipeline drugs market are intravenous, oral, subcutaneous, topical, and parenteral.
-
What are the key molecule types in the Sickle Cell Disease pipeline drugs market?
The molecule types in the Sickle Cell Disease pipeline drugs market are small molecule, monoclonal antibody, peptide, and recombinant protein.
-
Which are the key companies in the Sickle Cell Disease pipeline drugs market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Hematological Disorders reports